Welcome to our dedicated page for 23Andme Holding Co news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23Andme Holding Co stock.
News for 23andMe Holding Co. (Nasdaq: ME), now renamed Chrome Holding Co. in SEC filings, centers on its evolution as a genetics-led consumer healthcare, biotechnology, and research company and on significant corporate restructuring events. Press releases describe 23andMe as a human genetics company with a mission to help people access, understand, and benefit from the human genome, and as a genetics-led consumer healthcare and research or biopharmaceutical company empowering a healthier future.
Visitors to this news feed can review updates on Chapter 11 proceedings, including the company’s voluntary filing in the U.S. Bankruptcy Court for the Eastern District of Missouri, court approvals of first-day motions, and the launch of a court-supervised sale process. Releases detail the company’s efforts to obtain debtor-in-possession financing, sell substantially all of its assets, and address operational, financial, and legal challenges, as well as subsequent SEC reports on the approved and completed sale of assets to 23andMe Research Institute.
The news stream also covers strategic and operational developments such as the exploration of strategic alternatives, workforce reductions, discontinuation of the Therapeutics operating segment, and restructuring initiatives aimed at cost reductions. Financial results announcements provide context on revenue trends, changes in operating expenses, and management’s previously stated concerns about liquidity and ability to continue as a going concern before the Chapter 11 filing.
In addition, 23andMe’s news highlights product and research updates, including new genetic reports for 23andMe+ Premium members on topics such as osteoporosis and homocysteine (MTHFR-related) levels, the launch of Discover23 for biopharma collaborators, and collaborations with partners like Mirador Therapeutics. Telehealth and preventive health initiatives, such as GLP-1 weight loss offerings on the Lemonaid Health platform and a comprehensive longevity service, also appear in company communications.
For investors and observers following ME-related developments, this page aggregates company-issued news on genetics products, research collaborations, telehealth services, financial performance, governance changes, and the ongoing Chapter 11 restructuring and asset sale process.
23andMe Appoints New Chief Scientific Officer
23andMe Holding Co. (Nasdaq: ME) announced the appointment of Dr. Joseph R. Arron as Chief Scientific Officer, bringing nearly 20 years of experience in biotech drug discovery. Dr. Arron will lead the company's therapeutic programs across multiple disease areas, including immuno-oncology and cardiovascular diseases. Previously at Genentech, he oversaw extensive research initiatives. This strategic addition aims to enhance 23andMe's drug discovery pipeline and further its mission in genetics-based therapeutics.
23andMe Holding Co. (Nasdaq: ME) announced the redemption of all outstanding Public and Private Warrants to purchase shares of its Class A common stock. The redemption price is set at $0.10 per Warrant, effective by 5:00 p.m. NYC time on December 22, 2021. The redemption is triggered if the Class A common stock's Reference Value equals or exceeds $10.00 per share for twenty trading days within a thirty-day trading period. Holders may exercise their Warrants until the Redemption Date, after which unexercised Warrants will become void.
23andMe Holding Co. (Nasdaq: ME) reported a Q2 FY2022 revenue of $55 million, a 7% increase year-over-year. The company completed the acquisition of Lemonaid Health, enhancing its telemedicine offerings. The consumer services segment accounted for 81% of total revenue. Operating expenses rose to $74 million due to R&D and marketing investments. The net loss improved to $17 million from $36 million in the prior year, driven by favorable changes in warrant liabilities. Cash reserves increased to $701 million following a prior business combination.
23andMe Holding Co. (Nasdaq: ME) announced its participation in three upcoming virtual investor conferences scheduled for November and December 2021. The conferences include:
- Credit Suisse 30th Annual Healthcare Conference on November 11 at 12:10 pm ET
- Piper Sandler 33rd Annual Healthcare Conference with a pre-recorded chat available the week of November 22
- Evercore ISI 4th Annual HealthCONx Conference on December 2 at 2:15 pm ET
Webcasts of these presentations will be accessible on the company's investor website.
23andMe Holding Co. (Nasdaq: ME) announced the appointment of Dr. Sandra Hernández to its Board of Directors. Dr. Hernández, currently the President & CEO of the California Health Care Foundation, brings a wealth of experience in improving healthcare access, particularly for underserved communities. Her leadership is expected to enhance 23andMe’s efforts in delivering personalized healthcare experiences. Anne Wojcicki, CEO of 23andMe, emphasized Dr. Hernández’s expertise as vital for the company’s mission of providing affordable and accessible care.
23andMe Holding Co. (Nasdaq: ME) will report its financial results for the fiscal year 2022 second quarter on November 10, 2021, after market close. A conference call is scheduled for 4:30 p.m. Eastern Time. Shareholders can submit questions via the Say Technologies platform ahead of the earnings call. 23andMe has established itself as a leader in consumer genetics, with multiple FDA authorizations for health risk reports and a robust research platform that has facilitated over 180 publications on genetic diseases.
23andMe Holding Co. (Nasdaq: ME) has acquired Lemonaid Health, a telemedicine platform, enhancing its consumer healthcare offerings. This acquisition aims to provide personalized healthcare, leveraging genetics as a foundation. Lemonaid's services will integrate into 23andMe’s consumer business, led by its co-founder Paul Johnson as Vice President. The deal emphasizes better access to affordable healthcare and aligns with 23andMe's mission of empowering individuals through genetic information.
23andMe Holding Co. (Nasdaq: ME) has signed a definitive merger agreement to acquire Lemonaid Health, Inc. for approximately $400 million, with 25% in cash and 75% in shares. This acquisition aims to enhance 23andMe's telemedicine capabilities, allowing for personalized healthcare through a combination of genetics and telemedicine services. The deal is anticipated to close by the end of 2021, with Lemonaid’s CEO, Paul Johnson, transitioning to lead 23andMe's consumer business.
23andMe Holding Co. (Nasdaq: ME) will report its fiscal year 2022 second-quarter financial results before the market opens on November 10, 2021. A conference call will be held at 4:30 p.m. ET to discuss these results alongside business progress. 23andMe is noted for its pioneering role in consumer genetics and has multiple FDA authorizations for genetic health risk reports. The company has built the world's largest crowdsourced platform for genetic research, contributing to over 180 publications in genetic studies.
23andMe Holding Co. (Nasdaq: ME) announced its participation in the Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 8:20 a.m. PT. Investors can access the live webcast on the company's website. The session will provide updates on the company's developments in consumer genetics and therapeutics. Founded in 2006, 23andMe aims to enhance public access to genetic information and has the world's largest crowdsourced genetic research platform.